Treatment Outcomes Associated With Dupilumab Use in Patients With Atopic Dermatitis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Treatment Outcomes Associated With Dupilumab Use in Patients With Atopic Dermatitis

Published:2021-12-15 Issue: Volume: Page:
ISSN:2168-6068
Container-title:JAMA Dermatology
language:en
Short-container-title:JAMA Dermatol

Author:

Strober Bruce¹,Mallya Usha G.²,Yang Min³,Ganguli Sohini²,Gadkari Abhijit⁴,Wang Jessie³,Sierka Debra²,Delevry Dimittri⁴,Kimball Alexa B.⁵

Affiliation:

1. Yale University School of Medicine, New Haven, Connecticut, and Central Connecticut Dermatology, Cromwell, Connecticut

2. Sanofi, Cambridge, Massachusetts

3. Analysis Group, Inc., Boston, Massachusetts

4. Regeneron Pharmaceuticals Inc, Tarrytown, New York

5. Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, Massachusetts

Publisher

American Medical Association (AMA)

Subject

Dermatology

Link

https://jamanetwork.com/journals/jamadermatology/articlepdf/2787271/jamadermatology_strober_2021_oi_210064_1639414836.78519.pdf

Reference54 articles.

1. Illness perception in individuals with atopic dermatitis.;Wittkowski;Psychol Health Med,2007

2. The patient-reported disease burden in adults with atopic dermatitis: a cross-sectional study in Europe and Canada.;de Bruin-Weller;J Eur Acad Dermatol Venereol,2020

3. A real-world study evaluating adeQUacy of Existing Systemic Treatments for patients with moderate-to-severe Atopic Dermatitis (QUEST-AD): baseline treatment patterns and unmet needs assessment.;Wei;Ann Allergy Asthma Immunol,2019

4. Inadequate disease control, treatment dissatisfaction, and quality-of-life impairments among US patients receiving topical therapy for atopic dermatitis.;Anderson;Dermatol Ther (Heidelb),2021

5. Targeting key proximal drivers of type 2 inflammation in disease.;Gandhi;Nat Rev Drug Discov,2016

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: Up to 5-year results from the daily practice BioDay registry;Journal of the American Academy of Dermatology;2024-08

2. Practical Management of the JAK1 Inhibitor Abrocitinib for Atopic Dermatitis in Clinical Practice: Special Safety Considerations;Dermatology and Therapy;2024-07-02

3. Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2);American Journal of Clinical Dermatology;2024-03-25

4. Systemic Biologic Management of Atopic Dermatitis;Advances in Experimental Medicine and Biology;2024

5. How to use the Harmonising Outcome Measures for Eczema Core Outcome Set for atopic dermatitis trials: a users’ guide;British Journal of Dermatology;2023-12-20

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3